Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models

por Hiroshima, Yukihiko, Zhang, Yong, Zhao, Ming, Zhang, Nan, Murakami, Takashi, Maawy, Ali, Mii, Sumiyuki, Uehara, Fuminari, Yamamoto, Mako, Miwa, Shinji, Yano, Shuya, Momiyama, Masashi, Mori, Ryutaro, Matsuyama, Ryusei, Chishima, Takashi, Tanaka, Kuniya, Ichikawa, Yasushi, Bouvet, Michael, Endo, Itaru, Hoffman, Robert M.
Publicado 2015

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

por Li, Ting, Wang, Biyun, Wang, Zhonghua, Ragaz, Joseph, Zhang, Jian, Sun, Si, Cao, Jun, Lv, Fangfang, Wang, Leiping, Zhang, Sheng, Ni, Chen, Wu, Zhenhua, Xie, Jie, Hu, Xichun
Publicado 2015

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

por Fukuda, Takayo, Tanabe, Masahiko, Kobayashi, Kokoro, Fukada, Ippei, Takahashi, Shunji, Iwase, Takuji, Ito, Yoshinori
Publicado 2015

Anti-Neoplastic Cytotoxicity of Gemcitabine-(C(4)-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3)

por Coyne, CP, Jones, Toni, Bear, Ryan
Publicado 2013

Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer

por Gori, Stefania, Inno, Alessandro, Fiorio, Elena, Foglietta, Jennifer, Ferro, Antonella, Gulisano, Marcella, Pinotti, Graziella, Gubiotti, Marta, Cavazzini, Maria Giovanna, Turazza, Monica, Duranti, Simona, De Simone, Valeria, Iezzi, Laura, Bisagni, Giancarlo, Spazzapan, Simon, Cavanna, Luigi, Saggia, Chiara, Bria, Emilio, Cretella, Elisabetta, Vici, Patrizia, Santini, Daniele, Fabi, Alessandra, Garrone, Ornella, Frassoldati, Antonio, Amaducci, Laura, Saracchini, Silvana, Evangelisti, Lucia, Barni, Sandro, Gamucci, Teresa, Mentuccia, Lucia, Laudadio, Lucio, Zoboli, Alessandra, Marchetti, Fabiana, Bogina, Giuseppe, Lunardi, Gianluigi, Boni, Luca
Publicado 2015

Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis

por Ye, Peng, Zhang, Meizhuo, Fan, Shuqiong, Zhang, Tianwei, Fu, Haihua, Su, Xinying, Gavine, Paul R., Liu, Qiang, Yin, Xiaolu
Publicado 2015

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)

por Hasegawa, Yoshie, Tanino, Hirokazu, Horiguchi, Jun, Miura, Daishu, Ishikawa, Takashi, Hayashi, Mitsuhiro, Takao, Shintaro, Kim, Seung Jin, Yamagami, Kazuhiko, Miyashita, Masaru, Konishi, Muneharu, Shigeoka, Yasushi, Suzuki, Masato, Taguchi, Tetsuya, Kubota, Tomoyuki, Akazawa, Kouhei, Kohno, Norio
Publicado 2015

The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang

por Zhang, Li, Wang, Yuling, Bai, Ge, Zhang, Jianqing, Yang, Mei, Ma, Xiaoli
Publicado 2015

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer....

por Mouttet, D., Laé, M., Caly, M., Gentien, D., Carpentier, S., Peyro-Saint-Paul, H., Vincent-Salomon, A., Rouzier, R., Sigal-Zafrani, B., Sastre-Garau, X., Reyal, F.
Publicado 2016

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

por De Mattos-Arruda, Leticia, Bottai, Giulia, Nuciforo, Paolo G., Di Tommaso, Luca, Giovannetti, Elisa, Peg, Vicente, Losurdo, Agnese, Pérez-Garcia, José, Masci, Giovanna, Corsi, Fabio, Cortés, Javier, Seoane, Joan, Calin, George A., Santarpia, Libero
Publicado 2015

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

por Richman, Susan D, Southward, Katie, Chambers, Philip, Cross, Debra, Barrett, Jennifer, Hemmings, Gemma, Taylor, Morag, Wood, Henry, Hutchins, Gordon, Foster, Joseph M, Oumie, Assa, Spink, Karen G, Brown, Sarah R, Jones, Marc, Kerr, David, Handley, Kelly, Gray, Richard, Seymour, Matthew, Quirke, Philip
Publicado 2016

Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study

por Sun, Jia-Yuan, Wu, San-Gang, Li, Feng-Yan, Lin, Huan-Xin, He, Zhen-Yu
Publicado 2016

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B

por Kirouac, Daniel C., Du, Jinyan, Lahdenranta, Johanna, Onsum, Matthew D., Nielsen, Ulrik B., Schoeberl, Birgit, McDonagh, Charlotte F.
Publicado 2016

Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer

por Takahashi, Naoki, Furuta, Koh, Taniguchi, Hirokazu, Sasaki, Yusuke, Shoji, Hirokazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Hamaguchi, Tetsuya, Shimada, Yasuhiro, Yamada, Yasuhide
Publicado 2015

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer()

por Azim, Hamdy A., Kassem, Loay, Treilleux, Isabelle, Wang, Qing, El Enein, Mona Abu, Anis, Shady E., Bachelot, Thomas
Publicado 2016

HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway

por Chi, Feng, Wu, Rong, Jin, Xueying, Jiang, Min, Zhu, Xike
Publicado 2016

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer

por Gallagher, Christopher M., More, Kenneth, Kamath, Tripthi, Masaquel, Anthony, Guerin, Annie, Ionescu-Ittu, Raluca, Gauthier-Loiselle, Marjolaine, Nitulescu, Roy, Sicignano, Nicholas, Butts, Elizabeth, Wu, Eric Q., Barnett, Brian
Publicado 2016

High expression of integrin β6 in association with the Rho–Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers

por Desai, Krisha, Nair, Madhumathy G., Prabhu, Jyothi S., Vinod, Anupama, Korlimarla, Aruna, Rajarajan, Savitha, Aiyappa, Radhika, Kaluve, Rohini S., Alexander, Annie, Hari, P. S., Mukherjee, Geetashree, Kumar, Rekha V., Manjunath, Suraj, Correa, Marjorrie, Srinath, B. S., Patil, Shekhar, Prasad, M. S. N., Gopinath, K. S., Rao, Raman N., Violette, Shelia M., Weinreb, Paul H., Sridhar, T. S.
Publicado 2016

Dual-Labeled Near-Infrared/(99m)Tc Imaging Probes Using PAMAM-Coated Silica Nanoparticles for the Imaging of HER2-Expressing Cancer Cells

por Yamaguchi, Haruka, Tsuchimochi, Makoto, Hayama, Kazuhide, Kawase, Tomoyuki, Tsubokawa, Norio
Publicado 2016

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

por Meyer, Saskia, Nederend, Maaike, Jansen, J.H. Marco, Reiding, Karli R., Jacobino, Shamir R., Meeldijk, Jan, Bovenschen, Niels, Wuhrer, Manfred, Valerius, Thomas, Ubink, Ruud, Boross, Peter, Rouwendal, Gerard, Leusen, Jeanette H.W.
Publicado 2015